In:
Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 142, No. Suppl_4 ( 2020-11-17)
Abstract:
Background: Extracorporeal CPR (E-CPR) is a lifesaving method for refractory cardiac arrest (CA), and IABP has been often used as the additional circulatory support. However, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) increase damaged left ventricular (LV) afterload. The percutaneous microaxial pump, IMPELLA, can reduce damaged LV preload and afterload with circulatory support. Concomitant use of VA-ECMO and IMPELLA (ECPELLA) may have significant effect on clinical outcome. Objective: This study is to evaluate the effects of ECPELLA on clinical outcome of patients with out of hospital cardiac arrest (OHCA) or CA at the emergency room (ERCA) who underwent E-CPR. Method: We retrospectively reviewed 140 consecutive patients who underwent E-CPR from January 2012 through May 2020 in our institute. Seventy-four in-hospital CA patients were excluded, and 66 patients with OHCA or ERCA were recruited. Patients were divided into three groups ECEPLLA (n=13), ECMO with IABP (n=40), and ECMO alone (n=13). The primary endpoint was 30-day mortality. Secondary endpoint was good neurological outcome at hospital discharge defined as cerebral performance categories (CPC) of 1 or 2. Result: There were no significant differences in age, sex, OHCA, acute coronary syndrome in all three groups. The rate of shockable rhythm was higher in the ECPELLA and ECMO with IABP groups than ECMO alone. ECPELLA had the shortest time from CA to ECMO support compared with other groups. The 30-day survival and favorable neurological prognosis rates were significantly higher in the ECPELLA group, compared with other groups (ECPELLA: 61% vs. IABP: 18% vs. ECMO alone: 15%; P=0.008, ECPELLA: 38% vs. IABP: 8% vs. ECMO alone: 8%; P=0.03). Multivariate cox regression analysis including age, sex, time from CA to ECMO support and ECPELLA revealed that age (hazard ratio [HR], 1.36 (10 years increase), 95% confidence interval [CI] , 1.11-1.67, P=0.04), male (HR, 2.42, 95%CI, 1.04-5.66, P=0.04), time from CA to ECMO support (HR, 1.01, 95%CI, 1.01-1.03, P=0.04), and ECPELLA (HR, 0.35, 95%CI, 0.13-0.91, P=0.03) were significantly associated with 30-day mortality. Conclusion: ECPELLA could improve 30-day mortality and neurological outcome in OHCA or ERCA patients who underwent E-CPR.
Type of Medium:
Online Resource
ISSN:
0009-7322
,
1524-4539
DOI:
10.1161/circ.142.suppl_4.268
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2020
detail.hit.zdb_id:
1466401-X
Bookmarklink
